Nu-Med Plus (NUMD) Restructuring Costs (2023 - 2026)
Nu-Med Plus' (NUMD) quarterly Restructuring Costs came in at $210.0 in Q2 2026, down 30.0% quarter-over-quarter from $300.0 in Q1 2024.
Powered by 
Analysis
Nu-Med Plus (NUMD) Restructuring Costs (2023 - 2026) Analysis & Trends
Nu-Med Plus has disclosed Restructuring Costs across 3 years of filings, most recently posting $210.0 for Q2 2026.
- In Q2 2026, Restructuring Costs changed N/A year-over-year to $210.0; the TTM figure through Jun 2026 stood at $210.0 (changed N/A YoY), while the FY2025 annual figure was $58.0, down 80.67% from the prior year.
- Restructuring Costs came in at $210.0 for Q2 2026 at Nu-Med Plus, down from $300.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $3300.0 in Q3 2023 to a low of $210.0 in Q2 2026.
- Average Restructuring Costs over 3 years is $1702.5, with a median of $1650.0 recorded in 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 210.00 |
| Mar 31, 2024 | 300.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 3,300.00 |